Background: Adjunctive Cilostazol (Pletaal짰) to dual antiplatelet therapy (triple antiplatelet) is known to reduce restenosis and associated with favorable clinical outcomes in diabetes. However, there is limited data on triple antiplatelet therapy for diabetic patients (pts) in real world clinical practice scenario. Method: The study population consisted of 301 consecutive pts who underwent elective percutaneoous coronary intervention (PCI) with drug-eluting stent (DES) from April 2006 to February 2009. Pts presented with acute myocardial infarction (AMI) and non-diabetes were excluded for the analysis. Usage of adjunctive Cilostazol was depending on physician���s discretion. Cilostazol was administered by 200mg post-loading and then 100mg bid for at least one month. Clinical and angiographic outcomes at 6 months of triple group were compared with those of dual antiplatelet group. Results: Out of 301 pts, 111 pts (36.9%) received adjunctive Cilostazol. Pts in Triple group had worse angiographic characteristics including more left main, diffuse long, ostial lesions and also calcified lesions. Despite the worse baseline characteristics, multivariate analysis revealed that pts in the Triple group showed less target lesion and vessel revascularization (TLR and TVR). Although it was not statistically significant, there were 2 stent thrombosis (ST) in Dual group whereas no ST in Triple group (Table). Conclusion: Diabetic pts presenting with chronic stable angina receives Cilostazol as adjunctive therapy along with dual antiplatelets at least more than one month reduced repeat revascularization up to 6 months despite of worse baseline characteristics compared with those of dual antiplatelet group.